Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a drug called Corabotase IPN10200 compared to a placebo for treating adults with Cervical Dystonia CD. CD causes abnormal movements and symptoms in the head and neck, such as neck pain, stiffness, and headaches. The condition may involve brain regions that control movement and could be influenced by genetic and environmental factors. This study is a Phase II trial aiming to find out if Corabotase can provide longer-lasting relief than current treatments. Participants will receive a single intramuscular injection of either Corabotase at one of three doses Dose A, Dose B, or Dose C or a placebo on Day 1 of the treatment period. The injections target muscles in the head, neck, and shoulders. The study includes two periods a Screening Period lasting up to 4 weeks to determine eligibility, followed by a 36-week Treatment Period. Participants may continue some other medications during the study, which will be recorded. During the study, participants will attend 10 in-person clinic visits and one remote visit phone call, or 12 in-person visits if receiving Dose C. They will undergo blood and urine tests, physical and neurological exams, and clinical evaluations. Participants will also fill out questionnaires throughout the study. The main outcome measured is the change in severity of CD symptoms using a specific rating scale at Week 4. Total participation lasts about 40 weeks approximately 9 months.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.
Actively Recruiting
Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284 in patients experiencing agitation associated with Alzheimers dementia. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to understand how ITI-1284 affects agitation symptoms in this population. Participants receive either ITI-1284 at doses of 10 mg or 20 mg as a rapidly disintegrating tablet taken once daily under the tongue, or a matching placebo tablet taken the same way. The study uses a flexible-dose design and assigns participants randomly to one of the two groups. Treatment is administered daily during the trial. Throughout the study, participants agitation is measured using the Cohen-Mansfield Agitation Inventory total score at Week 12 as the primary outcome. Additional assessments include the Clinical Global Impression-Severity score at Week 12. Participants are monitored for safety and tolerability, and the study lasts until completion around December 2027.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ML-007C-MA in adults aged 55 to 90 years who experience hallucinations and delusions associated with Alzheimers Disease Psychosis ADP. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare ML-007C-MA with a placebo to see how well it treats these symptoms, as measured by the Neuropsychiatric Inventory-Clinician NPI-C Hallucinations and Delusions score. Participants will receive either ML-007C-MA, dosed as 1051.5 mg twice daily or 2103 mg twice daily, or placebo tablets. The study uses a parallel design and the treatment period lasts 7 weeks. The main focus is to observe changes from the start to the end of treatment in hallucinations and delusions scores, along with other secondary measures related to agitation, aggression, and clinical global impressions. During the study, participants will be closely monitored through assessments including the NPI-C HD score at baseline and after 7 weeks of treatment. Additional evaluations include clinical global impressions and agitationaggression scores for some participants. The study involves regular check-ins to track symptom changes and adherence to the treatment. Participants remain under careful medical observation throughout, with the study concluding in December 2027.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.
Actively Recruiting
Researchers are conducting a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This study aims to understand how ACP-204 affects psychosis symptoms in participants aged 55 to under 85 years. It compares two doses of ACP-204 against a placebo over a six-week period. Participants are assigned to one of three groups receiving 30 mg of ACP-204 once daily, 60 mg of ACP-204 once daily, or a placebo once daily. The medication is provided as a capsule taken orally. The study lasts six weeks, during which participants take their assigned treatment daily while remaining unaware of their group assignment. Throughout the trial, participants will be monitored regularly to assess changes in their psychosis symptoms using the SAPS-LBDP total score at week 6. Safety and tolerability will also be evaluated. The study includes screening for eligibility, regular visits during treatment, and assessments to track symptom changes and any side effects over the six-week treatment period.
Actively Recruiting
Researchers are conducting a 52-week, open-label extension study to evaluate ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This Phase 3 trial aims to assess long-term treatment effects and safety in participants who have previously completed an antecedent ACP-204 study. The study is sponsored by ACADIA Pharmaceuticals Inc. and focuses on adults aged 55 to 84 years. Participants will receive ACP-204 capsules taken orally once daily, starting at 30 mg. The dose may be adjusted during the trial, allowing for increases to 60 mg or reductions back to 30 mg depending on treatment response. The study design includes a single treatment group with no placebo or comparison groups, and treatment is provided openly without masking. Throughout the 52 weeks, participants and their study partners or caregivers will attend all study visits and complete assessments under supervision. Researchers will monitor for treatment-emergent adverse events as the primary outcome. Participants must be able to provide informed consent or assent with consent from a legally authorized representative. Safety and efficacy evaluations will be conducted regularly to ensure participant well-being during the study period.